Becton Dickinson and Co (NYSE:BDX) has earned an average rating of “Buy” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $264.45.
A number of analysts recently weighed in on the stock. Morgan Stanley reduced their target price on shares of Becton Dickinson and from $255.00 to $250.00 and set an “equal weight” rating for the company in a report on Friday, May 10th. Barclays raised their target price on shares of Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a report on Monday, April 15th. Raymond James reduced their target price on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a report on Tuesday, March 19th. Zacks Investment Research cut shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a report on Monday, April 22nd. Finally, KeyCorp restated an “overweight” rating and set a $262.00 target price (down from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th.
In related news, EVP Patrick Kaltenbach sold 191 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $241.03, for a total value of $46,036.73. Following the completion of the transaction, the executive vice president now owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Samrat S. Khichi sold 16,085 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the transaction, the executive vice president now directly owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The disclosure for this sale can be found here. Insiders sold a total of 21,154 shares of company stock valued at $4,955,775 in the last ninety days. Company insiders own 0.12% of the company’s stock.
A number of institutional investors have recently bought and sold shares of BDX. Advisors Asset Management Inc. boosted its holdings in shares of Becton Dickinson and by 7.1% in the 4th quarter. Advisors Asset Management Inc. now owns 42,658 shares of the medical instruments supplier’s stock worth $9,612,000 after purchasing an additional 2,840 shares during the period. Gantzert Investment Co. LLC ADV purchased a new position in Becton Dickinson and during the 4th quarter valued at $2,209,000. Comerica Securities Inc. boosted its holdings in Becton Dickinson and by 31.2% during the 4th quarter. Comerica Securities Inc. now owns 2,742 shares of the medical instruments supplier’s stock valued at $618,000 after acquiring an additional 652 shares during the period. Oregon Public Employees Retirement Fund boosted its holdings in Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 6,545,502 shares during the period. Finally, Canada Pension Plan Investment Board boosted its holdings in Becton Dickinson and by 3,791.8% during the 4th quarter. Canada Pension Plan Investment Board now owns 53,162 shares of the medical instruments supplier’s stock valued at $11,977,000 after acquiring an additional 51,796 shares during the period. 84.54% of the stock is owned by hedge funds and other institutional investors.
Shares of Becton Dickinson and stock traded up $2.86 on Monday, hitting $252.01. The company had a trading volume of 1,552,144 shares, compared to its average volume of 1,247,633. The business has a 50-day simple moving average of $236.09. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82. The stock has a market cap of $67.20 billion, a P/E ratio of 22.89, a PEG ratio of 1.84 and a beta of 1.12. Becton Dickinson and has a 52 week low of $208.62 and a 52 week high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $4.20 billion during the quarter, compared to analysts’ expectations of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The business’s revenue was down .6% on a year-over-year basis. During the same period last year, the firm posted $2.65 earnings per share. On average, equities analysts expect that Becton Dickinson and will post 11.69 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 7th were paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend was Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is 27.97%.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: The primary rules of Elliott Wave theory
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.